CLL without immediate treatment: making sense of active monitoring

Being told that chronic lymphocytic leukaemia (CLL) does not need treatment immediately can feel difficult to reconcile with the word “leukaemia”. Active monitoring is a planned approach for some patients, not an instruction to ignore the diagnosis. A second opinion should clarify why monitoring is recommended and how the team will recognise a change.

Ask for the reason monitoring is appropriate now

The NCI describes observation among the options for CLL when treatment is not yet needed. The decision is individual. Ask the haematologist which features of the current condition support the recommendation and which findings would lead to reassessment. Do not use a high lymphocyte number alone to decide that treatment must start or that the current advice is wrong.

Write down the doctor’s explanation in your own words and ask whether it is accurate. For example, the useful summary is not simply “no treatment”; it is “monitoring is recommended for these documented reasons, with these planned checks”.

Turn monitoring into a written agreement

• When is the next appointment and which tests are actually prescribed?
• Who reviews results if they are performed at a different laboratory?
• Which symptoms should be reported before the next appointment?
• How can the team be reached outside routine scheduling?
• What would prompt a discussion about starting treatment?

Ask what to do if an appointment is missed or a result has not been reviewed. Monitoring is less reassuring when responsibility is unclear, even if the proposed interval is clinically appropriate.

Prepare a focused second-opinion file

Provide the original diagnostic report, dated blood-count trends, the current assessment and any imaging or genetic tests already performed. Include medicines, relevant infections and symptoms discussed with the clinician. Do not purchase a broad new test package before the reviewing specialist explains whether it would change the decision.

The main question can be concise: “Do the available findings support monitoring at present, and is the follow-up plan complete?” That is more useful than requesting the most intensive available treatment without establishing that treatment is indicated.

A visit abroad should have a defined purpose

If considering a consultation in Turkey, ask what could be decided by reviewing existing records and what requires examination. A second opinion may confirm the home team’s monitoring plan. That can be a valuable result; it does not make the consultation unsuccessful.

For costs, distinguish a specialist review from an open-ended diagnostic package. Ask whether additional tests will be discussed before they are ordered and how the resulting plan will be shared with the local haematologist. Clarify which team retains responsibility after the visit.

New or worsening symptoms should be reported according to the agreed plan, rather than saved for the next overseas appointment. Do not start, stop or change any medicine on the basis of this article. Its purpose is to make an individual monitoring recommendation understandable and practical.

A practical next step

For the practical arrangements, see An oncology second opinion: when it helps and how to prepare.

Sources

• NCI: Chronic Lymphocytic Leukemia Treatment